Explore active biotech venture capital investors by stage, thesis, and check sizes. This directory highlights fund sizes, recent filings, and sector focus to help you prioritize investor outreach and improve match quality.
Complete database of 31 venture capital funds investing in biotech startups. Find the right investor with $33B in combined assets under management.
The biotech venture capital ecosystem has reached unprecedented scale, with 31 specialized funds managing $33B in assets.Investment activity has shown 43% growth year-over-year, reflecting strong investor confidence in the sector's long-term prospects.
In 2026, biotech startups attracted $12Bacross 672 funding rounds, with the average fund size reaching$281M. This represents a maturing ecosystem where specialized funds are increasingly focusing on vertical-specific expertise.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
Investing in revolutionary biotech companies that are transforming industries through innovative technology and scalable business models.
There are 31 active VC funds specializing in biotech investments, managing a combined $33B in assets under management. This represents one of the largest concentrations of specialized capital in the venture ecosystem, with funds ranging from $50M micro-funds to $2B+ growth-stage vehicles. The sector has attracted significant institutional capital due to its43% growth trajectory and strong exit potential.
Biotech startups raise an average of $15M in Series A funding, with typical ownership ranging from 23-31%. This is above the cross-industry average due to the capital-intensive nature of many biotech business models and longer development cycles. Series B rounds average $30M, reflecting the sector's ability to scale efficiently once product-market fit is achieved.
Top-performing biotech VCs have generated 4x average returns average returnsover the past decade, with the best funds creating 17 unicorn companies. Leading funds like Biotech Ventures A have demonstrated consistent performance through multiple market cycles, combining deep domain expertise with extensive portfolio support. Success rates for Series A investments reach 81% among top-quartile funds.
The typical biotech funding process takes 4-6 months, from initial pitch to signed term sheet. This includes 2-4 weeks for initial screening, 4-8 weeks for due diligence, and 2-4 weeks for final negotiations and documentation. Biotech startups often require longer diligence periods due to technical complexity and regulatory considerations, but experienced sector-focused VCs can move faster due to their domain expertise.
Top biotech VCs prioritize technical differentiation, large addressable markets, and experienced teamswith deep domain knowledge. They look for startups that can demonstrate clear competitive moats, scalable business models, and strong early customer traction. Regulatory compliance, intellectual property position, and go-to-market strategy are particularly important in biotech. The best VCs also value founders who can articulate long-term vision and have the technical depth to execute complex roadmaps.
Yes, biotech VCs deployed $12B in 2026across 672 transactions, showing continued strong appetite for quality deals. While overall VC activity has normalized from peak 2021 levels, biotech remains a priority sector for most institutional investors. Hot subsectors include AI-powered biotech, Next-gen biotech platforms, Enterprise biotech solutions, which are seeing particularly strong investor interest and premium valuations.
Last updated: 1/11/2026 | Data aggregated from 31 VC funds, 672 deals, and 45 successful exits |About our methodology